WATERTOWN, Mass.--(BUSINESS WIRE)--Lyndra Therapeutics, a clinical-stage biopharmaceutical company pioneering long-acting oral therapies, today announced a strategic collaboration with Thermo ...

Nurix Therapeutics (NRIX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jeet ...

Our research in Clinical Pharmacy & Pharmacy Practice focuses on optimising ... and ensuring the safe and effective delivery of therapeutics. We work on nanoparticle-based drug delivery, long-acting ...

Feb. 05, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq ... today provided an update on the progress of its late-stage clinical programs for lead neuroscience asset BXCL501, as ...

Kymera Therapeutics announced its clinical development plans for 2025, focusing on its oral degrader programs targeting immunological diseases. The company is currently conducting a Phase 1 trial ...

A phase 3 clinical trial application is aimed for submission in Q2 2021 for ARCT-021 to evaluate efficacy and safety. A key challenge for RNA-based therapeutics is handling the drug product from ...

Mersana Therapeutics, Inc. recently disclosed encouraging updates in a Form 8-K report filed with the Securities and Exchange Commission. The company unveiled positive initial clinical data from ...